Correction: Merger and Financing
Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) announced an all-share merger, with Scancell acquiring Neuphoria. The combined company plans a Nasdaq listing under SCLT. Financing totals up to $89m. A correction updates pro forma net cash to £59.2m and private placement gross proceeds to $39.1m.
How this was made
The 30-second read
Why it matters
The only new information is the correction of (1) the GBP figure for expected pro forma net cash (£59.2m) and (2) a footnote stating expected aggregate gross proceeds from the Private Placement ($39.1m). Deal structure, ownership split, and financing components are otherwise unchanged.
Market read
This is a deal-amendment update that corrects financing math and cash conversion figures, with limited incremental trading signal beyond confirming the revised numbers.
What to watch
Traders should still verify whether the corrected GBP figures affect any deal-related ratios, dilution expectations, or financing condition models used in valuation.
Background
The release amends a prior “Merger and Financing” announcement dated 23 July 2026, tied to an all-share acquisition of Neuphoria by Scancell and a planned Nasdaq listing.
Ticker impact
Neuphoria is the merger counterparty, and the amended release corrects the expected pro forma net cash and Private Placement gross proceeds figures.
Modest impact at most, as the correction does not alter the stated ownership split or CVR framework.
The text specifies corrections to GBP conversion and a footnote, while stating all other details remain unchanged.
Market effects
Reinforces ongoing capital-raising and Nasdaq uplisting activity in US-listed oncology biotech, but provides no new sector-wide regulatory or clinical catalyst.
UK AIM and US Nasdaq cross-listing dynamics remain in focus for small-cap biotech financing.
US investor access and Phase 3 funding runway narrative continues, but the amendment itself is not a global macro driver.
Counterpoint
Because the amendment says all other details remain unchanged, the market may treat this as administrative and discount it quickly.
Key entities
- public_companyScancell Holdings plc
AIM-listed biotech planning to acquire Neuphoria and uplist to Nasdaq under symbol SCLT.
- public_companyNeuphoria Therapeutics Inc.
Nasdaq-listed biotech being acquired by Scancell in an all-share merger, with CVRs for partnered assets.
- financing_counterpartyBlackRock-managed funds/accounts
Named as counterpart in a non-binding term sheet for debt financing up to $25m.
